Despite great strides in treatment, asthma remains a major unmet medical need, as there are still cohorts of patients whose condition is poorly controlled.
The cost of care of poorly controlled asthma, both in terms of medication and hospitalisation, is growing exponentially. This is creating a very real clinical need for a treatment which is both effective and convenient to enhance patient compliance.
There are significant challenges with the current treatment approaches:
- Limited scope of current medication due to the multiple causes of allergic and non-allergic asthma
- Lack of patient compliance with some treatments due to steroid phobia that leads to poor control
Peptinnovate is developing transformational, broad spectrum medicines, with the potential for disease modification to target both the allergic and non-allergic causes of asthma.
At Peptinnovate our aim is to deliver a treatment that is both effective and convenient to enable even the severest of sufferers to live a normal life without regular hospitalisation or daily medication i.e. a low intervention rate, no matter what triggers their attacks.